MedTrace Logo

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-12-02

No results posted yet for this study

Summary

The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).

Conditions

  • Transfusion Related Complication

Interventions

DRUG

SNO

S-nitrosylating agent (SNO) Inhalation

DRUG

Normal Saline

Normal Saline transfusion

DRUG

Red Blood Cell

Blood transfusion (RBCs)

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • James Reynolds

    lead OTHER

Principal Investigators

  • James D. Reynolds, PhD · Case Western Reserve University

  • Mada Helou, MD · University Hospitals Cleveland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-25
Primary Completion
2028-02-29
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03999229 on ClinicalTrials.gov